Algorithme Pharma Speaks at Society of Toxicology (SOT) 2014 Annual Meeting

Algorithme Pharma Speaks at Society of Toxicology (SOT) 2014 Annual Meeting (Laval, Québec, Canada Mar, 04 2014) Algorithme Pharma, a full service early stage clinical research organization, is pleased to be presenting at this year’s Society of Toxicology (SOT) meeting on the subject of Dried Blood Spots (DBS) in Toxicology: "Can Science Overcome the Regulatory Challenge?.” In this session, Dr. Fabio Garofolo, Vice-President Bioanalytical Services, Algorithme Pharma will focus on specific methods to overcome the limitations of Dried Blood Spot analysis and highlight the Pre-Cut technique for use in analyzing New Molecular Entities (NME) and Biomarkers. The speaking session will include the recent IQ (International Consortium for Innovation & Quality in Pharmaceutical Development) recommendations on refining DBS to meet regulatory requirements. Attendees will be provided with an overview of key points to consider for DBS analysis and scientific insights on the following DBS issues: hematocrit impact, dilution effect, internal standard techniques & stability considerations. To register for this speaking session or for more information, please visit http://www.algopharm.com/en/sot-annual-meeting-2014/exhibitor-session. About Algorithme Pharma Algorithme Pharma, an Altasciences Company, is a full service provider focused on early stage clinical research. With over 20 years of experience, Algorithme Pharma successfully completes more than 200 clinical trials annually. Support services include large and small molecule Bioanalysis, Data Management, Biostatistics, Regulatory Support, Clinical Pharmacology and Project Management. Information: Algorithme Pharma Catherine Konidas Vice-President Global Business Development Tel.: 450-973-6077 [email protected] | www.algopharm.com

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.